BofA/Merrill Lynch Starts Paratek Pharmaceuticals (PRTK) at Neutral
Tweet
Share
E-mail
Get Alerts PRTK Hot Sheet
Price: $1.93 --0%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 31
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 11 | New: 31
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
BofA/Merrill Lynch analyst Jason Gerberry initiates coverage on Paratek Pharmaceuticals (NASDAQ: PRTK) with a Neutral rating and a price target of $13.00.
For an analyst ratings summary and ratings history on Paratek Pharmaceuticals click here. For more ratings news on Paratek Pharmaceuticals click here.
Shares of Paratek Pharmaceuticals closed at $10.30 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA client flows to US stocks biggest since October
- Daiwa Securities Starts Deere (DE) at Outperform (2)
- BofA Securities Upgrades Paramount Global (PARA) to Buy Citing Asset Value
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
